nodes	percent_of_prediction	percent_of_DWPC	metapath
Antipyrine—migraine—Prednisone—psoriasis	0.492	1	CpDpCtD
Antipyrine—CYP2A6—Methoxsalen—psoriasis	0.0427	0.092	CbGbCtD
Antipyrine—CYP2C8—Tazarotene—psoriasis	0.0327	0.0704	CbGbCtD
Antipyrine—CYP1A2—Clobetasol propionate—psoriasis	0.031	0.0668	CbGbCtD
Antipyrine—PTGS2—Triamcinolone—psoriasis	0.0248	0.0534	CbGbCtD
Antipyrine—PTGS2—Betamethasone—psoriasis	0.0213	0.0458	CbGbCtD
Antipyrine—CYP2A6—Prednisolone—psoriasis	0.0208	0.0447	CbGbCtD
Antipyrine—CYP2B6—Cholecalciferol—psoriasis	0.0184	0.0397	CbGbCtD
Antipyrine—CYP1A2—Methoxsalen—psoriasis	0.0163	0.0351	CbGbCtD
Antipyrine—CYP2D6—Hydroxyurea—psoriasis	0.0147	0.0316	CbGbCtD
Antipyrine—CYP2C8—Cholecalciferol—psoriasis	0.0139	0.03	CbGbCtD
Antipyrine—SLC22A6—Cyclosporine—psoriasis	0.0139	0.03	CbGbCtD
Antipyrine—PTGS2—Dexamethasone—psoriasis	0.0124	0.0267	CbGbCtD
Antipyrine—CYP2A6—Dexamethasone—psoriasis	0.0122	0.0264	CbGbCtD
Antipyrine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0121	0.026	CbGbCtD
Antipyrine—CYP2C19—Cholecalciferol—psoriasis	0.0117	0.0252	CbGbCtD
Antipyrine—CYP3A4—Calcitriol—psoriasis	0.011	0.0236	CbGbCtD
Antipyrine—CYP2C9—Cholecalciferol—psoriasis	0.00973	0.0209	CbGbCtD
Antipyrine—CYP2C8—Hydrocortisone—psoriasis	0.00971	0.0209	CbGbCtD
Antipyrine—CYP2C8—Cyclosporine—psoriasis	0.00917	0.0197	CbGbCtD
Antipyrine—CYP2D6—Cholecalciferol—psoriasis	0.0089	0.0192	CbGbCtD
Antipyrine—CYP3A4—Methoxsalen—psoriasis	0.00854	0.0184	CbGbCtD
Antipyrine—CYP2C19—Prednisone—psoriasis	0.00811	0.0175	CbGbCtD
Antipyrine—CYP2E1—Dexamethasone—psoriasis	0.00808	0.0174	CbGbCtD
Antipyrine—CYP2B6—Dexamethasone—psoriasis	0.00797	0.0172	CbGbCtD
Antipyrine—CYP2C19—Cyclosporine—psoriasis	0.00769	0.0166	CbGbCtD
Antipyrine—SLC22A6—Methotrexate—psoriasis	0.00737	0.0159	CbGbCtD
Antipyrine—CYP2C9—Cyclosporine—psoriasis	0.00639	0.0138	CbGbCtD
Antipyrine—CYP2C8—Dexamethasone—psoriasis	0.00604	0.013	CbGbCtD
Antipyrine—CYP2D6—Cyclosporine—psoriasis	0.00585	0.0126	CbGbCtD
Antipyrine—CYP3A4—Cholecalciferol—psoriasis	0.00566	0.0122	CbGbCtD
Antipyrine—CYP2C19—Dexamethasone—psoriasis	0.00506	0.0109	CbGbCtD
Antipyrine—CYP3A4—Triamcinolone—psoriasis	0.0049	0.0106	CbGbCtD
Antipyrine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0049	0.0106	CbGbCtD
Antipyrine—CYP2C9—Dexamethasone—psoriasis	0.00421	0.00907	CbGbCtD
Antipyrine—CYP3A4—Betamethasone—psoriasis	0.00421	0.00906	CbGbCtD
Antipyrine—CYP3A4—Prednisolone—psoriasis	0.00415	0.00894	CbGbCtD
Antipyrine—CYP3A4—Hydrocortisone—psoriasis	0.00394	0.00848	CbGbCtD
Antipyrine—CYP3A4—Prednisone—psoriasis	0.00392	0.00844	CbGbCtD
Antipyrine—CYP2D6—Dexamethasone—psoriasis	0.00385	0.00829	CbGbCtD
Antipyrine—CYP3A4—Cyclosporine—psoriasis	0.00372	0.008	CbGbCtD
Antipyrine—CYP3A4—Dexamethasone—psoriasis	0.00245	0.00527	CbGbCtD
Antipyrine—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000508	0.157	CbGdCrCtD
Antipyrine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000506	0.0124	CbGpPWpGaD
Antipyrine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000442	0.0109	CbGpPWpGaD
Antipyrine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000437	0.0107	CbGpPWpGaD
Antipyrine—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000407	0.126	CbGdCrCtD
Antipyrine—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000396	0.122	CbGdCrCtD
Antipyrine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000391	0.00959	CbGpPWpGaD
Antipyrine—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000379	0.00932	CbGpPWpGaD
Antipyrine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000359	0.00881	CbGpPWpGaD
Antipyrine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000357	0.00877	CbGpPWpGaD
Antipyrine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000352	0.00865	CbGpPWpGaD
Antipyrine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00035	0.00859	CbGpPWpGaD
Antipyrine—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000345	0.00847	CbGpPWpGaD
Antipyrine—CYP2C18—Biological oxidations—CYP2S1—psoriasis	0.000313	0.00768	CbGpPWpGaD
Antipyrine—CYP2C18—Metapathway biotransformation—CYP2S1—psoriasis	0.000308	0.00757	CbGpPWpGaD
Antipyrine—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000307	0.0949	CbGdCrCtD
Antipyrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000302	0.00742	CbGpPWpGaD
Antipyrine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000298	0.00733	CbGpPWpGaD
Antipyrine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000289	0.00711	CbGpPWpGaD
Antipyrine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000283	0.00696	CbGpPWpGaD
Antipyrine—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.00028	0.00688	CbGpPWpGaD
Antipyrine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000277	0.0068	CbGpPWpGaD
Antipyrine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00027	0.00663	CbGpPWpGaD
Antipyrine—CYP2C18—Tryptophan metabolism—CAT—psoriasis	0.00027	0.00663	CbGpPWpGaD
Antipyrine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000266	0.00654	CbGpPWpGaD
Antipyrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000248	0.00609	CbGpPWpGaD
Antipyrine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000246	0.00604	CbGpPWpGaD
Antipyrine—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000246	0.076	CbGdCrCtD
Antipyrine—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000246	0.076	CbGdCrCtD
Antipyrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000245	0.00602	CbGpPWpGaD
Antipyrine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000245	0.00601	CbGpPWpGaD
Antipyrine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000243	0.00596	CbGpPWpGaD
Antipyrine—TRPA1—Transmembrane transport of small molecules—CP—psoriasis	0.000242	0.00595	CbGpPWpGaD
Antipyrine—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000239	0.0738	CbGdCrCtD
Antipyrine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000233	0.00571	CbGpPWpGaD
Antipyrine—TRPA1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000231	0.00568	CbGpPWpGaD
Antipyrine—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000222	0.00546	CbGpPWpGaD
Antipyrine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000219	0.00537	CbGpPWpGaD
Antipyrine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00021	0.00516	CbGpPWpGaD
Antipyrine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000207	0.00509	CbGpPWpGaD
Antipyrine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000201	0.00495	CbGpPWpGaD
Antipyrine—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000201	0.00495	CbGpPWpGaD
Antipyrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000201	0.00494	CbGpPWpGaD
Antipyrine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000199	0.0049	CbGpPWpGaD
Antipyrine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.00019	0.00468	CbGpPWpGaD
Antipyrine—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000186	0.0574	CbGdCrCtD
Antipyrine—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000186	0.0574	CbGdCrCtD
Antipyrine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000184	0.00451	CbGpPWpGaD
Antipyrine—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000183	0.0045	CbGpPWpGaD
Antipyrine—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000182	0.00447	CbGpPWpGaD
Antipyrine—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000181	0.0561	CbGdCrCtD
Antipyrine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000177	0.00434	CbGpPWpGaD
Antipyrine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00017	0.00419	CbGpPWpGaD
Antipyrine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000164	0.00403	CbGpPWpGaD
Antipyrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000162	0.00398	CbGpPWpGaD
Antipyrine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000161	0.00394	CbGpPWpGaD
Antipyrine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00016	0.00394	CbGpPWpGaD
Antipyrine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00016	0.00393	CbGpPWpGaD
Antipyrine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000154	0.00379	CbGpPWpGaD
Antipyrine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000154	0.00378	CbGpPWpGaD
Antipyrine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000152	0.00372	CbGpPWpGaD
Antipyrine—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000151	0.0037	CbGpPWpGaD
Antipyrine—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000148	0.00365	CbGpPWpGaD
Antipyrine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000148	0.00365	CbGpPWpGaD
Antipyrine—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000145	0.00355	CbGpPWpGaD
Antipyrine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000135	0.00331	CbGpPWpGaD
Antipyrine—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	0.000134	0.0033	CbGpPWpGaD
Antipyrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000131	0.00323	CbGpPWpGaD
Antipyrine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.00013	0.0032	CbGpPWpGaD
Antipyrine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.00013	0.00319	CbGpPWpGaD
Antipyrine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00013	0.00319	CbGpPWpGaD
Antipyrine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000128	0.00315	CbGpPWpGaD
Antipyrine—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000127	0.00311	CbGpPWpGaD
Antipyrine—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000124	0.00305	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000119	0.00291	CbGpPWpGaD
Antipyrine—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000117	0.00288	CbGpPWpGaD
Antipyrine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000116	0.00285	CbGpPWpGaD
Antipyrine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000115	0.00281	CbGpPWpGaD
Antipyrine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000114	0.00281	CbGpPWpGaD
Antipyrine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000113	0.00277	CbGpPWpGaD
Antipyrine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000113	0.00277	CbGpPWpGaD
Antipyrine—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000112	0.0346	CbGdCrCtD
Antipyrine—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000112	0.0346	CbGdCrCtD
Antipyrine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000112	0.00275	CbGpPWpGaD
Antipyrine—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000111	0.00272	CbGpPWpGaD
Antipyrine—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000109	0.0338	CbGdCrCtD
Antipyrine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000107	0.00262	CbGpPWpGaD
Antipyrine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000106	0.00261	CbGpPWpGaD
Antipyrine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000106	0.0026	CbGpPWpGaD
Antipyrine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00259	CbGpPWpGaD
Antipyrine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000104	0.00257	CbGpPWpGaD
Antipyrine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000104	0.00254	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000103	0.00254	CbGpPWpGaD
Antipyrine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000103	0.00253	CbGpPWpGaD
Antipyrine—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000102	0.00251	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000101	0.00248	CbGpPWpGaD
Antipyrine—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000101	0.00247	CbGpPWpGaD
Antipyrine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.65e-05	0.00237	CbGpPWpGaD
Antipyrine—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	9.58e-05	0.00235	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.34e-05	0.00229	CbGpPWpGaD
Antipyrine—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	9.15e-05	0.00225	CbGpPWpGaD
Antipyrine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	9.05e-05	0.00222	CbGpPWpGaD
Antipyrine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.92e-05	0.00219	CbGpPWpGaD
Antipyrine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.91e-05	0.00219	CbGpPWpGaD
Antipyrine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.77e-05	0.00216	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	8.73e-05	0.00215	CbGpPWpGaD
Antipyrine—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	8.24e-05	0.00202	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	8.21e-05	0.00202	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	8.21e-05	0.00202	CbGpPWpGaD
Antipyrine—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	8.12e-05	0.00199	CbGpPWpGaD
Antipyrine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.87e-05	0.00193	CbGpPWpGaD
Antipyrine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.81e-05	0.00192	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	7.55e-05	0.00185	CbGpPWpGaD
Antipyrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.45e-05	0.00183	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	7.17e-05	0.00176	CbGpPWpGaD
Antipyrine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.98e-05	0.00172	CbGpPWpGaD
Antipyrine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.89e-05	0.00169	CbGpPWpGaD
Antipyrine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	6.79e-05	0.00167	CbGpPWpGaD
Antipyrine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.73e-05	0.00165	CbGpPWpGaD
Antipyrine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.7e-05	0.00165	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	6.66e-05	0.00164	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	6.52e-05	0.0016	CbGpPWpGaD
Antipyrine—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.37e-05	0.00157	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—NDUFA5—psoriasis	6.29e-05	0.00154	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	6.2e-05	0.00152	CbGpPWpGaD
Antipyrine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.16e-05	0.00151	CbGpPWpGaD
Antipyrine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.03e-05	0.00148	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	5.99e-05	0.00147	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—IL4—psoriasis	5.97e-05	0.00147	CbGpPWpGaD
Antipyrine—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.79e-05	0.00142	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.74e-05	0.00141	CbGpPWpGaD
Antipyrine—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	5.44e-05	0.00134	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—CYP2S1—psoriasis	5.35e-05	0.00131	CbGpPWpGaD
Antipyrine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.22e-05	0.00128	CbGpPWpGaD
Antipyrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.19e-05	0.00128	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—LEP—psoriasis	5.05e-05	0.00124	CbGpPWpGaD
Antipyrine—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.96e-05	0.00122	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.78e-05	0.00117	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	4.74e-05	0.00116	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—NOS2—psoriasis	4.7e-05	0.00115	CbGpPWpGaD
Antipyrine—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	4.65e-05	0.00114	CbGpPWpGaD
Antipyrine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	4.64e-05	0.00114	CbGpPWpGaD
Antipyrine—PTGS2—C-MYB transcription factor network—CD4—psoriasis	4.57e-05	0.00112	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	4.56e-05	0.00112	CbGpPWpGaD
Antipyrine—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.44e-05	0.00109	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.34e-05	0.00107	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—NDUFA5—psoriasis	4.05e-05	0.000995	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—NDUFA5—psoriasis	3.83e-05	0.000941	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.81e-05	0.000935	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	3.79e-05	0.000932	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.78e-05	0.000928	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.75e-05	0.000921	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.72e-05	0.000913	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.61e-05	0.000886	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.61e-05	0.000886	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—CYP2S1—psoriasis	3.44e-05	0.000846	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	3.35e-05	0.000824	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.27e-05	0.000804	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—CYP2S1—psoriasis	3.26e-05	0.0008	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—NDUFA5—psoriasis	3.22e-05	0.00079	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.2e-05	0.000786	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.09e-05	0.000759	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—NDUFA5—psoriasis	3.03e-05	0.000744	CbGpPWpGaD
Antipyrine—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3e-05	0.000737	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3e-05	0.000737	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.95e-05	0.000725	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.81e-05	0.000689	CbGpPWpGaD
Antipyrine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.81e-05	0.000689	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—CYP2S1—psoriasis	2.73e-05	0.000672	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.63e-05	0.000646	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.62e-05	0.000643	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—CARM1—psoriasis	2.61e-05	0.000641	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—CYP2S1—psoriasis	2.57e-05	0.000632	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.44e-05	0.000599	CbGpPWpGaD
Antipyrine—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	2.38e-05	0.000585	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.34e-05	0.000574	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—TNF—psoriasis	2.33e-05	0.000573	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.23e-05	0.000547	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.18e-05	0.000535	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.15e-05	0.000528	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.13e-05	0.000523	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.12e-05	0.000521	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—TP53—psoriasis	2.06e-05	0.000505	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.04e-05	0.000501	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.99e-05	0.000488	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.99e-05	0.000488	CbGpPWpGaD
Antipyrine—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.88e-05	0.000463	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.85e-05	0.000455	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.83e-05	0.000449	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.82e-05	0.000447	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.81e-05	0.000445	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.81e-05	0.000443	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.7e-05	0.000417	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—CARM1—psoriasis	1.68e-05	0.000413	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—CAT—psoriasis	1.61e-05	0.000394	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—CARM1—psoriasis	1.59e-05	0.000391	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.59e-05	0.00039	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.57e-05	0.000386	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.55e-05	0.00038	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.43e-05	0.000352	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.4e-05	0.000345	CbGpPWpGaD
Antipyrine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.4e-05	0.000344	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—CARM1—psoriasis	1.34e-05	0.000328	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—CARM1—psoriasis	1.28e-05	0.000315	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—CARM1—psoriasis	1.26e-05	0.000309	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.25e-05	0.000307	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—APOE—psoriasis	1.25e-05	0.000307	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.19e-05	0.000293	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.17e-05	0.000286	CbGpPWpGaD
Antipyrine—CYP2C18—Metabolism—PPARG—psoriasis	1.09e-05	0.000267	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—CARM1—psoriasis	1.09e-05	0.000267	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	0.000256	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—CAT—psoriasis	1.03e-05	0.000254	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.02e-05	0.00025	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—CAT—psoriasis	9.78e-06	0.00024	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—CARM1—psoriasis	9.7e-06	0.000238	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.49e-06	0.000233	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.07e-06	0.000223	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—CARM1—psoriasis	8.92e-06	0.000219	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—CARM1—psoriasis	8.84e-06	0.000217	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.27e-06	0.000203	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—CAT—psoriasis	8.21e-06	0.000202	CbGpPWpGaD
Antipyrine—PTGS2—Disease—HLA-A—psoriasis	8.16e-06	0.000201	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.11e-06	0.000199	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—APOE—psoriasis	8.04e-06	0.000198	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—CAT—psoriasis	7.89e-06	0.000194	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—CAT—psoriasis	7.73e-06	0.00019	CbGpPWpGaD
Antipyrine—PTGS2—Disease—APOE—psoriasis	7.62e-06	0.000187	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—APOE—psoriasis	7.6e-06	0.000187	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—CARM1—psoriasis	7.56e-06	0.000186	CbGpPWpGaD
Antipyrine—PTGS2—Disease—NOS2—psoriasis	7.1e-06	0.000174	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.06e-06	0.000174	CbGpPWpGaD
Antipyrine—PTGS1—Metabolism—PPARG—psoriasis	7e-06	0.000172	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—CAT—psoriasis	6.68e-06	0.000164	CbGpPWpGaD
Antipyrine—CYP2A6—Metabolism—PPARG—psoriasis	6.62e-06	0.000163	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—APOE—psoriasis	6.38e-06	0.000157	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—APOE—psoriasis	6.13e-06	0.000151	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—APOE—psoriasis	6.01e-06	0.000148	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—CAT—psoriasis	5.97e-06	0.000147	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—CARM1—psoriasis	5.83e-06	0.000143	CbGpPWpGaD
Antipyrine—PTGS2—Disease—TYK2—psoriasis	5.82e-06	0.000143	CbGpPWpGaD
Antipyrine—PTGS2—Metabolism—PPARG—psoriasis	5.56e-06	0.000137	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—CAT—psoriasis	5.49e-06	0.000135	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—CAT—psoriasis	5.44e-06	0.000134	CbGpPWpGaD
Antipyrine—CYP2B6—Metabolism—PPARG—psoriasis	5.34e-06	0.000131	CbGpPWpGaD
Antipyrine—PTGS2—Disease—CD4—psoriasis	5.26e-06	0.000129	CbGpPWpGaD
Antipyrine—CYP2E1—Metabolism—PPARG—psoriasis	5.23e-06	0.000129	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—APOE—psoriasis	5.19e-06	0.000128	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—CAT—psoriasis	4.65e-06	0.000114	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—APOE—psoriasis	4.64e-06	0.000114	CbGpPWpGaD
Antipyrine—CYP2C8—Metabolism—PPARG—psoriasis	4.52e-06	0.000111	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—APOE—psoriasis	4.26e-06	0.000105	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—APOE—psoriasis	4.23e-06	0.000104	CbGpPWpGaD
Antipyrine—PTGS2—Disease—STAT3—psoriasis	4.07e-06	0.0001	CbGpPWpGaD
Antipyrine—CYP2C19—Metabolism—PPARG—psoriasis	4.04e-06	9.92e-05	CbGpPWpGaD
Antipyrine—CYP2D6—Metabolism—PPARG—psoriasis	3.71e-06	9.12e-05	CbGpPWpGaD
Antipyrine—CYP2C9—Metabolism—PPARG—psoriasis	3.68e-06	9.04e-05	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—APOE—psoriasis	3.61e-06	8.87e-05	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—CAT—psoriasis	3.59e-06	8.81e-05	CbGpPWpGaD
Antipyrine—CYP1A2—Metabolism—PPARG—psoriasis	3.15e-06	7.73e-05	CbGpPWpGaD
Antipyrine—PTGS2—Disease—IL6—psoriasis	2.84e-06	6.99e-05	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—APOE—psoriasis	2.79e-06	6.85e-05	CbGpPWpGaD
Antipyrine—CYP3A4—Metabolism—PPARG—psoriasis	2.43e-06	5.96e-05	CbGpPWpGaD
